The antigen 85 (Ag85) complex of Mycobacterium tuberculosis comprises secreted mycolyltransferases essential for cell wall biosynthesis and envelope integrity. Although extensively studied as immunodominant antigens and targets of small-molecule inhibitors, their potential for antibody-mediated functional modulation remains underexplored. In this review, we re-evaluate the Ag85 complex from a mechanistic and therapeutic perspective, focusing on its accessibility, structural organization, and functional vulnerabilities within the mycobacterial cell envelope. We highlight the distinction between antigen recognition and functional modulation, noting that conventional antibody responses often target immunodominant but functionally irrelevant epitopes. We propose that nanobodies represent a promising platform for targeting conformationally or spatially restricted regions of Ag85 enzymes that are not readily accessible to conventional antibodies. Based on structural and biochemical insights, we outline a framework in which Ag85-targeting nanobodies act as sensitizing agents that perturb cell wall biosynthesis and enhance susceptibility to antibiotics or cell wall-degrading enzymes. We further discuss key challenges, including antigen accessibility under physiological conditions, intracellular localization, and nanobody stability, which may influence the feasibility of this approach.
Recombinant expression of Mycobacterium tuberculosis antigen 85B (Ag85B) in Escherichia coli is frequently limited by poor solubility and accumulation of the target protein in inclusion bodies. Fusion to thioredoxin (Trx) can improve solubility; however, subsequent removal of the fusion partner using commercial proteases adds an additional purification step and increases process complexity. Here, we developed an alternative approach in which optimization of cultivation conditions promoted both soluble expression and intracellular removal of the N-terminal Trx partner. A recombinant Trx-Ag85B-FLAG-His₆ construct was expressed in E. coli SHuffle T7, and the effects of medium composition, inducer concentration, cell density at induction, temperature, and cultivation time were evaluated. Under initial LB-medium conditions, the recombinant protein accumulated predominantly in the insoluble fraction as a full-length product of approximately 51 kDa, consistent with retention of the Trx fusion partner. Optimization using Super Broth-medium, 0.1 mM IPTG, induction at OD₆₀₀ 0.8–1.0, and cultivation at 16 °C substantially increased the soluble fraction. Prolonged incubation under these conditions resulted in a FLAG-positive product with a molecular mass below 35 kDa, consistent with removal of the N-terminal Trx and retention of the C-terminal Ag85B-FLAG-His₆ region. Addition of β-mercaptoethanol to the culture medium did not substantially affect accumulation of soluble protein. These findings support a model in which moderate expression kinetics facilitate soluble Ag85B folding, followed by endogenous intracellular proteolytic processing of the fusion protein. This strategy may simplify recombinant Ag85B production by reducing the need for an external protease-mediated tag-removal step.